The insulin receptor: A new anticancer target for peroxisome proliferator-activated receptor-γ (PPARγ) and thiazolidinedione- PPARγ agonists

Endocrine-Related Cancer

Volumn 15, Issue 1, 2008, Pages 325-335

  Costa, V ^a   Foti, D ^a   Paonessa, F ^a   Chiefari, E ^a   Palaia, L ^a   Brunetti, G ^b   Gulletta, E ^a   Fusco, A ^c   Brunetti, A ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CHLORAMPHENICOL; DNA; GLUTATHIONE TRANSFERASE; INSULIN RECEPTOR; PEPTIDE HORMONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; TRANSCRIPTION FACTOR SP1; TYROSINE KINASE RECEPTOR;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL LINE; CELL MEMBRANE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA PROTEIN COMPLEX; GEL MOBILITY SHIFT ASSAY; GENETIC TRANSCRIPTION; GROWTH ACCELERATION; HUMAN; HUMAN CELL; LIVER CELL; METABOLISM; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN DNA INTERACTION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION;

3T3-L1 CELLS; ANIMALS; BLOTTING, WESTERN; BREAST NEOPLASMS; CARCINOMA, HEPATOCELLULAR; CCAAT-ENHANCER-BINDING PROTEIN-BETA; CELLS, CULTURED; CHROMATIN IMMUNOPRECIPITATION; DNA; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FIBROBLASTS; GLUTATHIONE TRANSFERASE; HMGA PROTEINS; HUMANS; IMMUNOPRECIPITATION; LIVER NEOPLASMS; MICE; PLASMIDS; PPAR GAMMA; RECEPTOR, INSULIN; RESPONSE ELEMENTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SP1 TRANSCRIPTION FACTOR; THIAZOLIDINEDIONES; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTOR AP-2; TRANSCRIPTION, GENETIC;

EID: 41349116750     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/ERC-07-0226     Document Type: Article

References (53)

1. Allred CD & Kilgore MW 2005 Selective activation of PPARγ in breast, colon, and lung cancer cell lines. Molecular and Cellular Endocrinology 235 21-29.
2. Araki E, Shimada F, Uzawa H, Mori M & Ebina Y 1987 Characterization of the promoter region of the human insulin receptor gene. Journal of Biological Chemistry 262 16186-16191.
3. Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-Lozano P, Chien KR, Koder A & Evans RM 1999 PPARγ is required for placental, cardiac, and adipose tissue development. Molecular Cell 4 585-595.
4. Berger J & Moller DE 2002 The mechanisms of action of PPARs. Annual Review of Medicine 53 409-435.
5. Brunetti A, Maddux BA, Wong KY & Goldfine ID 1989 Muscle cell differentiation is associated with increased insulin receptor biosynthesis and messenger RNA levels. Journal of Clinical Investigation 83 192-198.
6. Brunetti A, Foti D & Goldfine ID 1993 Identification of inique nuclear regulatory proteins for the insulin receptor gene, which appear during myocyte and adipocyte differentiation. Journal of Clinical Investigation 92 1288-1295.
7. Brunetti A, Manfioletti G, Chiefari E, Goldfine ID & Foti D 2001 Transcriptional regulation of human insulin receptor gene by the high-mobility-group protein HMGI-Y. FASEB Journal 15 492-500.
8. Burgermeister E & Seger R 2007 MAPK kinases as nucleocytoplasmic shuttles for PPARgamma. Cell Cycle 6 1539-1548.
9. Chou FS, Wng PS, Kulp S & Pinzone JJ 2007 Effects of thiazolidinediones on differentiation, proliferation, and apoptosis. Molecular Cancer Research 5 523-530.
10. Desvergne B & Wahli W 1999 Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocrine Reviews 20 649-688.
11. Elstner E, Müller C, Koshizuka K, Williamson EA, Park D, Asou H, Shintaku P, Said JW, Heber D & Koeffler HP 1998 Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. PNAS 95 8806-8811.
12. Farid NR, Shi Y & Zou M 1994 Molecular basis of thyroid cancer. Endocrine Reviews 15 202-232.
13. Foti D, Iuliano R, Chiefari E & Brunetti A 2003 A nucleoprotein complex containing Sp1, C/EBPβ, and HMGI-Y controls human insulin receptor gene transcription. Molecular and Cellular Biology 23 2720-2732.
14. Foti D, Chiefari E, Fedele M, Iuliano R, Brunetti L, Paonessa F, Manfioletti G, Barbetti F, Brunetti A, Croce CM et al. 2005 Lack of the architectural factor HMGA1 causes severe insulin resistance and diabetes in humans and mice. Nature Medicine 11 765-773.
15. Goldfine ID 1987 The insulin receptor: molecular biology and transmembrane signalling. Endocrine Reviews 8 235-255.
16. Govindarajan R, Ratnasinghe L, Simmons DL, Siegel ER, Midathada MV, Kim L, Kim PJ, Owens RJ & Lang NP 2007 Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. Journal of Clinical Oncology 25 1476-1481.
17. Grommes C, Landreth GE & Heneka MT 2004 Antineoplastic effects of peroxisome proliferator-activated receptor agonists. Lancet Oncology 5 419-429.
18. Han SW, Ritzenthaler JD, Rivera HN & Roman J 2005 Peroxisome proliferator-activated receptor-gamma ligands suppress fibronectin gene expression in human lung carcinoma cells: involvement of both CRE and Sp1. American Journal of Physiology. Lung Cellular and Molecular Physiology 289 L419-L428.
19. Hilakivi-Clarke L, Wang C, Kalil M, Riggins R & Pestell RG 2004 Nutritional modulation of the cell cycle and breast cancer. Endocrine-Related Cancer 11 603-622.
20. Hong J, Samudio I, Liu S, Abdelrahim M & Safe S 2004 Peroxisome proliferator-activated receptor y-dependent activation of p21 in Panc-28 pancreatic cancer cells involves Sp1 and Sp4 proteins. Endocrinology 145 5774-5785.
21. Keller H, Dreyer C, Medin J, Mahfoudi A, Ozato K & Wahli W 1993a Fatty acids and retinoids control lipid metabolism through the activation of peroxisome proliferator-activated receptors heterodimers. PNAS 90 2160-2164.
22. Keller H, Mahfoudi A, Dreyer C, Hihi AK, Medin J, Ozato K & Wahli W 1993b Peroxisome proliferator-activated receptors and lipid metabolism. Annals of the New York Academy of Sciences 684 157-173.
23. Kersten S, Desvergne B & Wahli W 2000 Roles of PPARs in health and disease. Nature 405 421-424.
24. Kliewer SA, Xu HE, Lambert MH & Willson TM 2001 Peroxisome proliferator-activated receptors: from genes to physiology. Recent Progress in Hormone Research 56 239-263.
25. Krey G, Mahfoudi A & Wahli W 1995 Functional interactions of peroxisome proliferator-activated receptor, retinoid-X receptor, and Sp1 in the transcriptional regulation of the acyl-coenzyme-A oxidase promoter. Molecular Endocrinology 9 219-231.
26. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkinson WO, Willson TM & Kliewer SA 1995 An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptorg (PPARγ). Journal of Biological Chemistry 270 12953-12956.
27. Maloney CA & Rees WD 2005 Gene-nutrient interactions during fetal development. Reproduction 130 401-410.
28. Mamula PW, McDonald AR, Brunetti A, Okabayashi Y, Wong KY, Maddux BA, Logsdon C & Goldfine ID 1990 Regulating insulin-receptor-gene expression by differentiation and hormones. Diabetes Care 13 288-301.
29. Martelli ML, Iuliano R, Le Pera I, Samà I, Monaco C, Cammarota S, Kroll T, Chiariotti L, Santoro M & Fusco A 2002 Inhibitory effects of peroxisome proliferator-activated receptor gamma on thyroid carcinoma cell growth. Journal of Clinical Endocrinology and Metabolism 87 4728-4735.
30. Milazzo G, Giorgino F, Damante G, Sung C, Stampfer MR, Vigneri R, Goldfine ID & Belfiore A 1992 Insulin receptor expression and function in human breast cancer cell lines. Cancer Research 52 3924-3930.
31. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, Fletcher C, Singer S & Spiegelman BM 1998 Terminal differentiation of human breast cancer through PPARγ. Molecular Cell 1 465-470.
32. Mulholland DJ, Dedhar S, Coetzee GA & Nelson CC 2005 Interaction of nuclear receptors with the Wnt/beta-catenin/Tcf signaling axis: Wnt you like to know? Endocrine Reviews 26 898-915.
33. Nishizawa H, Yamagata K, Shimomura I, Takahashi M, Kuriyama H, Kishida K, Hotta K, Nagaretani H, Maeda N, Matsuda M et al. 2002 Small heterodimer partner, an orphan nuclear receptor, augments peroxisome proliferator-activated receptor gamma transactivation. Journal of Biological Chemistry 277 1586-1592.
34. Nunez NP, Liu H & Meadows GG 2005 PPAR-gamma ligands and amino acid deprivation promote apoptosis of melanoma, prostate, and breast cancer cells. Cancer Letters 236 133-141.
35. Osborne CK, Monaco ME, Lippman ME & Kahn CR 1978 Correlation among insulin binding, degradation, and biological activity in human breast cancer cells in long-term tissue culture. Cancer Research 38 94-102.
36. Padilla J, Kaur K, Harris SG & Phipps RP 2000 PPAR-gamma-mediated regulation of normal and malignant B lineage cells. Annals of the New York Academy of Sciences 905 97-109.
37. Paonessa F, Foti D, Costa V, Chiefari E, Brunetti G, Leone F, Luciano F, Wu F, Lee AS, Gulletta E et al. 2006 Activator protein-2 overexpression accounts for increased insulin receptor expression in human breast cancer. Cancer Research 66 5085-5093.
38. Papageorgiou E, Pitulis N, Msaouel P, Lembessis P & Koutsilieris H 2007 The non-genomic crosstalk between PPARγ ligands and ERK 1/2 in cancer cell lines. Expert Opinion on Therapeutic Targets 11 1071-1085.
39. Patel L, Pass I, Coxon P, Downes CP, Smith SA & Macphee CH 2001 Tumor suppressor and anti-inflammatory actions of PPARgamma agonista are mediated via upregulation of PTEN. Current Biology 11 764-768.
40. Ramos-Nino ME, MacLean CD & Littenberg B 2007 Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System. BMC Medicine 5 17-24.
41. Rosen ED, Sarraf P, Troy AE, Bradwin G, Moore K, Milstone DS, Spiegelman BM & Mortensen RM 1999 PPARγ is required for the differentiation of adipose tissue in vivo and in vitro. Molecular Cell 4 611-617.
42. Saltiel AR & Olefsky JM 1996 Thiazolidinediones in the treatment of insulin resistance and tipe II diabetes. Diabetes 45 1661-1669.
43. Savkur RS & Miller AR 2006 Investigational PPAR-γ agonists for the treatment of Type 2 diabetes. Expert Opinion on Investigational Drugs 15 763-778.
44. Seino S, Seino M, Nishi S & Bell GI 1989 Structure of the human insulin receptor gene and characterization of its promoter. PNAS 86 114-118.
45. Sugawara A, Uruno A, Kudo M, Ikeda Y, Sato K, Taniyama Y, Ito S & Takeuchi K 2002 Transcription suppression of thromboxane receptor gene by peroxisome proliferator-activated receptor,-g via an interaction with Sp1 in vascular smooth muscle cells. Journal of Biological Chemistry 277 9676-9683.
46. Takata Y, Kitami Y, Yang Z-H, Nakamura M, Okura T & Hiwada H 2002 Vascular inflammation is negatively autoregulated by interaction between CCAAT/enhancer-binding protein d and peroxisome proliferator-activated receptor. Circulation Research 91 427-433.
47. Tan NS, Michalik L, Desvergne B & Wahli W 2005 Multiple expression control mechanisms of peroxisome proliferator-activated receptors and their target genes. Journal of Steroid Biochemistry and Molecular Biology 93 99-105.
48. Tontonoz PM, Hu E & Spiegelman BN 1994 Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 79 1147-1156.
49. Ullrich A, Bell JR, Chen EY, Herrera R, Petruzzelli LM, Dull TJ, Gray A, Coussens L, Liao YC, Tsubokawa M et al. 1985 Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature 313 756-761.
50. Vidal-Puig AJ, Considine RV, Jimenezlinan M, Werman A, Pories WJ, Caro JF & Flier JS 1997 Peroxisome proliferator-activated receptor gene expression in human tissues. Journal of Clinical Investigation 99 2416-2422.
51. Wang C, Fu M, D'Amico M, Albanese C, Zhou JN, Brownlee M, Lisanti MP, Chatterjee VK, Lazar MA & Pestell RG 2001 Inhibition of cellular proliferation through IkB kinase-indipendent and peroxisome proliferator- activated receptor γ-dependent repression of cyclin D1. Molecular and Cellular Biology 21 3057-3070.
52. Wang LH, Yang XY, Zhang X & Farrar WL 2007 Inhibition of adhesive interaction between multiple myeloma and bone marrow stromal cells by PPARγ crostalk with NF-kB and C/EBPβ. Blood 110 4373-4384.
53. White MF & Kahn CR 1994 The insulin signaling system. Journal of Biological Chemistry 269 1-4.